This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sheth, R. D. Articles by Bodensteiner, J. B. Search for Related Content PubMed PubMed Citation Articles by Sheth, R. D. Articles by Bodensteiner, J. B. Social Bookmarking                         What's this?

Clobazam for Intractable Pediatric Epilepsy

Department of Neurology and Pediatrics West Virginia University, Health Science Center, Morgantown, WV

Gabriel M. Ronen, MD

Department of Pediatrics McMaster University Medical Center, Hamilton, Ontario

Keith J. Goulden, MD

Department of Pediatrics The Glenrose Children Rehabilitation Hospital, Edmonton, Alberta

Sharon Penney, RN

Janeway Child Health Center St John's, Newfoundland, Canada

John B. Bodensteiner, MD

Department of Neurology and Pediatrics West Virginia University, Health Science Center, Morgantown, WV

We report our experience with add-on clobazam therapy over a 5-year period in 63 children with refractory epilepsy. The mean duration of epilepsy was 6.7 years. Children were followed for 15 to 64 months. Of 63 children, 57 were developmentally delayed, and 54 had a symptomatic/cryptogenic epilepsy. Forty-one percent became either seizure free or had a greater than 90% reduction in seizure frequency. Seizure frequency was reduced 50% to 90% in another 24%. The average daily dose of clobazam was 0.8 mg/kg. Thirty-five percent had the medication withdrawn for persistent or unacceptable side effects or the development of tolerance (seven patients). Side effects included severe aggressive outbursts, hyperactivity, insomnia, and depression with suicidal ideation. Clobazam is a useful add-on medication for 65% of children with epilepsy. Clinical utility may be limited by behavioral side effects in some patients. (J Child Neurol 1995;10:205-208).

Journal of Child Neurology, Vol. 10, No. 3, 205-208 (1995)
DOI: 10.1177/088307389501000306


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. G.W. Theis, G. Koren, R. Daneman, A. L. Sherwin, E. Menzano, M. Cortez, and P. Hwang Interactions of Clobazam With Conventional Antiepileptics in Children J Child Neurol, April 1, 1997; 12(3): 208 - 213. [Abstract] [PDF]